2015
DOI: 10.1016/j.jvir.2014.12.016
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of the Plasmatic and Parenchymal Elution Kinetics of Two Different Irinotecan-Loaded Drug-Eluting Embolics in a Pig Model

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2015
2015
2019
2019

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 22 publications
(9 citation statements)
references
References 21 publications
0
9
0
Order By: Relevance
“…In cTACE, cytotoxic chemotherapy is injected into the artery, which is then embolized with permanent agents (for example, polyvinyl alcohol particles) that are often size calibrated to target a specific arterial level . In DSM‐TACE, one or more cytotoxic agents are mixed with DSM‐TACEs, causing a temporary arterial occlusion . DEB‐TACE combines the two methods: permanent embolic agents are coated with cytotoxic therapies allowing for a controlled release of the drug into the tissues over hours or days.…”
Section: Regional Therapiesmentioning
confidence: 99%
See 1 more Smart Citation
“…In cTACE, cytotoxic chemotherapy is injected into the artery, which is then embolized with permanent agents (for example, polyvinyl alcohol particles) that are often size calibrated to target a specific arterial level . In DSM‐TACE, one or more cytotoxic agents are mixed with DSM‐TACEs, causing a temporary arterial occlusion . DEB‐TACE combines the two methods: permanent embolic agents are coated with cytotoxic therapies allowing for a controlled release of the drug into the tissues over hours or days.…”
Section: Regional Therapiesmentioning
confidence: 99%
“…160,161 In DSM-TACE, one or more cytotoxic agents are mixed with DSM-TACEs, causing a temporary arterial occlusion. 162 170 Radioembolization as salvage treatment is the most studied indication, with response rates of 17%-35% and stable disease in 61%-81% and median overall survival of 10 to 13 months. 171,172 Three phase III trials investigating radioembolization as first-line therapy for unresectable colorectal liver metastases were performed in 14 countries worldwide comparing systemic chemotherapy with systemic therapy and radioembolization.…”
Section: Livermentioning
confidence: 99%
“…After injection of DEBs, there is a controlled drug-release over several hours, and even days, within the treated tissue ( Fig. 1) [41]. Since type and dose of the chemotherapeutic can be selected individually and combined with a particular microsphere size and volume, DEB-TACE is considered as the most standardized procedure among TACE technologies.…”
Section: Chemoembolicsmentioning
confidence: 99%
“…In this context, embolization with the smallest available embolic agents, such as iodized oil (Lipiodol Ultra-Fluide; Guerbet, Roissy, France) and microspheres (e.g., Embozene 40 [CeloNova BioSciences, San Antonio, USA/Boston Scientific, Marlborough, USA]) bear the risk of complications, such as bile duct injury due to occlusion of the peribilliary plexus, non-target embolization due to arterio-venous shunts or occult arterial collateralization, and fulminant tumor necrosis with subsequent embolism of necrotic tissue [ 2 , 8 , 9 ]. In order to obtain a controllable level of distal arterial occlusion, narrow-size calibrated small microspheres with a defined and uniform diameter of ≤75μm are increasingly being used [ 6 , 7 , 10 ]. Embozene 40 and Tandem 40 microspheres (CeloNova BioSciences, San Antonio, USA/Boston Scientific, Marlborough, USA) are currently the smallest commercially available permanent microspheres that are clinically used for transarterial embolization [ 2 , 8 , 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…Animal models have been shown to be suitable for preclinical evaluation of the characteristics of embolic agents, such as visibility, vascular distribution, and effects on the treated tissue [ 7 , 10 13 ].…”
Section: Introductionmentioning
confidence: 99%